Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations

Oncologist

Volumn 12, Issue 5, 2007, Pages 543-554

  Jeung, Hei Cheul ^a   Sun, Young Rha ^a   Hoon, Kyo Kim ^b   Ho, Young Lim ^c   Kim, Samyong ^d   Si, Young Kim ^e   Soo, Jeong Gong ^f   Chan, Hee Park ^a   Joong, Bae Ahn ^a   Sung, Hoon Noh ^a   Hyun, Cheol Chung ^a,g  

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Chungnam National University College of Medicine   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Eulji University School of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Pharmacogenomics; Pharmacokinetics; Predictive marker; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; OXONATE POTASSIUM; TEGAFUR;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DNA MICROARRAY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEMATOCHEZIA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY SURFACE AREA; DNA, NEOPLASM; DRUG COMBINATIONS; DRUG EVALUATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXONIC ACID; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 34547923762     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-5-543     Document Type: Article

References (44)

1. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1997;72:37-41.
2. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
3. Dickson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroentrol Hepatol 2004;16:255-263.
4. Jeung HC, Rha SY, Noh SH et al. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience in single institute. Cancer 2001;91:2016-2025.
5. Sasaki T, Ibuka T, Imai K et al. [Low-dose methotrexate and sequential 5-FU treatment in advanced gastric cancer.] Gan To Kagaku Ryoho 1984; 11:2408-2413. Japanese.
6. Krook JE, O'Connell MJ, Wieand HS et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991;67:2454-2458.
7. Hsu CH, Yeh KH, Chen LT et al. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: An effective and low-toxic regimen for patients with poor general condition. Oncology 1997;54:275-280.
8. Yeh KH, Cheng AL. Gastric cancer associated with acute disseminated intravascular coagulation: Successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. Br J Haematol 1998; 100:769-772.
9. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: Implication for biochemical modulation. J Clin Oncol 1997;15:368-381.
10. Van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-2779.
11. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004; 15:85-106.
12. Sugimachi K, Maehara Y, Horikoshi N et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202-210.
13. Koizumi W, Kurihara M, Nakano S et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58: 191-197.
14. Sakata Y, Ohtsu A, Horikoshi N et al. Late phase II study of novel oral fluoropyrimidine anticancer drugs S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
15. Nagashima F, Ohtsu A, Yoshida S et al. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005;8:6-11.
16. Chollet P, Schoffski P, Weigang-Kohler K et al. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG). Eur J Cancer 2003;39:1264-1270.
17. Ilson D. Just when you thought the fluorouracil debate was over: S-1 and gastric cancer. J Clin Oncol 2005;23:6826-6828.
18. Hoff PM, Saad ED, Ajani JA et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-142.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
20. Matsushima E, Yoshida K, Kitamura R et al. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997;691:95-104.
21. Yamaoka K, Tanigawa Y. The Guide of Pharmacokinetics by Microcomputer. Tokyo: Nankoudou, 1983:169-178.
22. Seo MY, Rha SY, Yang SH et al. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Int J Mol Med 2004;13:17-24.
23. Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
24. Park CH, Jeong HJ, Choi YH et al. Systematic analysis of cDNA microarray-based CGH. Int J Mol Med 2006;17:261-267.
25. Shirao K, Ohtsu A, Takada H et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-2361.
26. Ikeda M, Furukawa H, Imamura H et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 2002;50:25-32.
27. Takahashi Y, Sakamoto J, Takeuchi T et al. A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy. Jpn J Clin Oncol 2004;34:342-345.
28. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005.
29. Zurita Saavedra AJ, Navarro Garcia M, Espanol I et al. UFT-induced haemolytic anemia. Cancer Chemother Pharmacol 2001;47:280-281.
30. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989;64:793-797.
31. Innocenti F, Liu W, Chen P et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005;15:295-301.
32. Shimada T, Yamazaki H, Guengerich FP. Ethnic related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403.
33. Kusumoto H, Maehara Y, Kusumoto T et al. Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. Eur J Surg Oncol 1988;14:685-689.
34. Schlag P, Schreml W. Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay. Cancer Res 1982;42:4086-4089.
35. Ravaud A, Borner M, Schellens JHM et al. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 2001;37:1642-1647.
36. Sakamoto J, Chin K, Kondo K et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006; 17:231-236.
37. Pisters PWT, Kelsen DP, Powell SM et al. Cancer of the stomach. In: De-Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Seventh Edition. Philadelphia: Lippincott Williams & Wilkins, 2005:909-944.
38. Yoshida R, Nakajima M, Nisimura K et al. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003;74:69-76.
39. Canaparo R, Casale F, Muntoni E et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000;50:146-153.
40. Jeung HC, Rha SY, Cho BC et al. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006;95:1637-1641.
41. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: Road to anticancer therapeutics nirvana? Oncogene 2003;22:6621-6628.
42. Olweus J, Terstappen LW, Thompson PA et al. Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Blood 1996;88:1594-1607.
43. Roskoski R Jr. Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005;337:1-13.
44. Shim GJ, Wang L, Andersson S et al. Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci U S A 2003;100:6694-6699.